Resources

PATH conducted a landscape analysis of cervical cancer screening in Kenya, Tanzania, and Uganda to clarify opportunities for HPV testing as a primary cervical cancer screening method in these countries. We conducted stakeholder interviews and meetings in each country to discuss the decision-making process for test introduction, potential advantages of HPV testing, and anticipated barriers to introduction and ways to overcome them.

To aid decision-makers interested in human papillomavirus (HPV) vaccine introduction or scale-up, in 2014–2016 the London School of Hygiene & Tropical Medicine and PATH conducted the first comprehensive review of HPV vaccine delivery experiences across 46 low- and middle-income countries.These experiences have helped countries learn valuable lessons about effective methods for garnering parental acceptance and reaching young adolescent girls with the vaccine, at relatively low delivery costs. The lessons learnt from these countries can provide critical information for policymakers and program planners on how best to prepare, deliver, and sustain HPV vaccines.Highlights include key findings and lessons from HPV vaccination experience across five themes: preparation, communications, delivery, achievements, and sustainability. Also addressed are the value of demonstration projects and potential HPV vaccination pitfalls.NOTE: In April 2025, the HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium published updated briefs that summarize new evidence on preparations, communications, effective delivery, sustaining programs, and pitfalls. The HAPPI Consortium is managed by JSI together with its partners Clinton Health Access Initiative (CHAI), the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health, Jhpiego, and PATH.

As with many other diseases, the burden of breast cancer falls most heavily on poor, marginalized, and rural women due to their unequal access to screening and treatment. This fact sheet describes PATH and our partners’ novel approach to improving early detection, diagnosis, and care in La Libertad, Peru, using a health care model that can be expanded and applied to other low-resource settings.

PATH's Community-Based Program for Breast Health expands breast-cancer care to women in low-resource settings in Peru. Together with our partners, we have tested and implemented novel approaches for the early detection, diagnosis, and care of women with breast cancer in the northern La Libertad region of Peru.

In 2014, PATH conducted interviews with stakeholders in Senegal and Uganda to assess receptivity to self-injection of the contraceptive, subcutaneous DMPA (DMPA-SC, brand name Sayana Press) as well as the evidence requirements and processes necessary to chart a course for adoption, introduction, and scale-up of self-injection as a service-delivery practice in the two countries. For more information, email FPoptions@path.org or visit www.path.org/dmpa-sc.